OctoPlus Expands Development Agreement With ESBATech on Controlled Release Product for Ophthalmic Indications
2/24/2011 8:19:03 AM
More...
|
Alcon Laboratories, Inc. (ACL) to Acquire Swiss Biotechnology Firm, ESBATech for $589 Million
9/14/2009 7:05:15 AM
More...
|
ESBATech: Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit Neovascularization
3/24/2009 10:57:57 AM
More...
|
ESBATech's Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study
2/24/2009 10:48:39 AM
More...
|
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
2/3/2009 10:42:52 AM
More...
|
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
1/9/2009 7:59:57 AM
More...
|
ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications Preclinical Pharmacokinetic Data to be Presented at the 7th International Symposium on Uveitis in Germany
9/8/2008 9:47:13 AM
More...
|
ESBATech Raises Additional $22M, Extending Series B Venture Financing Positive Results to Date Drive Decision to Expand its Proprietary Therapeutic Pipeline
8/7/2008 6:36:18 AM
More...
|
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
4/24/2008 7:40:21 AM
More...
|
ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
2/25/2008 8:10:59 AM
More...
|
|